Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion

P. G. Montaldo, F. Figoli, M. L. Zanette, R. Sorio, M. Zucchetti, U. Tirelli, Maurizio D’Incalci

Research output: Contribution to journalArticle

Abstract

The pharmacokinetics of etoposide (VP 16) and teniposide (VM 26) were studied after intrapleural administration to 3 patients with lung cancer and malignant pleural effusion. Comparison with the kinetic behavior of intravenously infused VP 16 and VM 26 in the same patients suggests that intrapleural drug delivery achieves higher and longer-lasting pleural concentrations, thus providing a theoretical basis for the palliative treatment of malignant pleural effusions. Although no systemic toxicity was observed after intrapleural administration of either drug, 1 of the 3 patients developed a transient asymptomatic hemorrhagic pleurisy during the first 2 days after the drug, alerting to the possible local toxicity of such treatment.

Original languageEnglish
Pages (from-to)55-61
Number of pages7
JournalOncology
Volume47
Issue number1
DOIs
Publication statusPublished - 1990

Keywords

  • Etoposide teniposide
  • Intracavitary chemotherapy
  • Lung cancer
  • Pharmacokinetics
  • Pleural effusion

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion'. Together they form a unique fingerprint.

  • Cite this